stocktrademan
10 years ago
$ANIK recent news/filings
bullish optionable
## source: finance.yahoo.com
Mon, 04 Aug 2014 22:31:31 GMT ~ Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
[at noodls] - Presentation to be Webcast Live at 10:30 a.m. ET BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 4, 2014-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, ...
read full: http://www.noodls.com/view/0B5B5CA243EAC93EE452713A2789C2BA9B25CCC0
*********************************************************
Mon, 04 Aug 2014 21:23:56 GMT ~ ANIKA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/140804/anik10-q.html
*********************************************************
Mon, 04 Aug 2014 20:05:00 GMT ~ Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
[Business Wire] - Anika Therapeutics, Inc. today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 10:30 a.m.
read full: http://finance.yahoo.com/news/anika-therapeutics-present-canaccord-genuity-200500108.html
*********************************************************
Thu, 31 Jul 2014 15:50:00 GMT ~ Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
read full: http://news.investors.com/073114-711208-stock-market-today-under-fire.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************
Wed, 30 Jul 2014 21:46:36 GMT ~ Anika Therapeutics Reports Second-Quarter 2014 Financial Results
[at noodls] - Total Revenue Grows 26% to $26.3 Million Commercial Launch of Monovisc® Generates $5 Million Milestone Payment Earnings per Share Increase to $0.60 from $0.40 a Year Earlier BEDFORD, Mass.--(BUSINESS WIRE)--Jul. ...
read full: http://www.noodls.com/view/CD5EA2386D5B9F27D25763A5F36B9CE9110D7A55
*********************************************************
$ANIK charts
basic chart ## source: stockcharts.com
basic chart ## source: eoddata.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ANIK company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ANIK/company-info
Ticker: $ANIK
OTC Market Place: Not Available
CIK code: 0000898437
Company name: Anika Therapeutics Inc.
Incorporated In: MA, USA
$ANIK share structure
## source: otcmarkets.com
Market Value: $574,549,373 a/o Aug 07, 2014
Shares Outstanding: 14,421,420 a/o May 01, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$ANIK extra dd links
Company name: Anika Therapeutics Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ANIK+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ANIK+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ANIK+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ANIK/news - http://finance.yahoo.com/q/h?s=ANIK+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ANIK/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ANIK/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ANIK+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ANIK
DTCC (dtcc.com): http://search2.dtcc.com/?q=Anika+Therapeutics+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Anika+Therapeutics+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Anika+Therapeutics+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ANIK
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000898437&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ANIK/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ANIK/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ANIK&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ANIK
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ANIK/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ANIK+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ANIK+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ANIK
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ANIK
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ANIK+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ANIK/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ANIK+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ANIK.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ANIK
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ANIK/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ANIK/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ANIK
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ANIK
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ANIK:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ANIK
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ANIK
$ANIK DD Notes ~ http://www.ddnotesmaker.com/ANIK
Gary_X
11 years ago
Anika Therapeutics (ANIK on the Nasdaq) is a hidden gem -- these are just a few of the many positives out there going on for this biotech company that has soared more than 280% in 2013.
Check out the rest of their info. at their website www.anikatherapeutics.com ; IMO everyone should be taking a small position in ANIK over the next few weeks, either through buying the Common or by buying some Call Options;
- Business Overview - Anika develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid ("HA"), also known as hyaluronan, a naturally occurring biocompatible polymer found in the body.
- Market Cap of about $455,000,000 as at Jan. 29, 2014,
- O/S of ONLY 14,000,000 shares and even lower float, with institutions and insiders holding greater than 65% of the float,
- They had more than $17M in Revenue, $5M in Net Income and more than $64M in cash alone from the quarter ending Sept. 30, 2013; 4Q and Full-Year 2013 earnings will probably be announced during the last week of Feb. 2014,
- Added to the S&P Smallcap 600 at the end of Nov. 2013; it forced institutions holding shares of companies in Biotech Indexes to buy into ANIK, causing the stock to soar from 31 to 38, before settling down to a current 33.
- On the FDA front, they have their flagship FDA-approved Orthovisc for the treatment of osteoarthritis of the knee and various other joints; they are awaiting FDA approval of a single injection version, Monovisc, which decision is due out any day now !! It is currently sold in Europe and Asia; they have a product Cingal, their second single-injection osteoarthritis product under development, is based on hyaluronic acid material with an added active therapeutic molecule designed to provide broad pain relief for a longer period of time. It is currently undergoing clinical trials in the U.S., currently at the patient recruitment stage, with results to be made available later in 2014,
- In addition to the current outstanding staff at the company, in Oct. 2013, Anika Therapeutics appointed John W. Sheets Jr. Ph.D. as its Chief Scientific Officer. Dr. Sheets comes from Boston Scientific, where he was Sr. V.P. of Corporate Research.
=================================================================
Read up on Anika Therapeutics --- do your DD --- and you may find as I did an untappes gem of a company with amazing things on the horizon !!
GLTA !!
surf1944
12 years ago
Anika Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
Fourth Quarter Revenue Increases 23% on Strong Sales of Orthovisc
Earnings Grow 48% to $0.31 per Share in Quarter and 32% to $0.82 per Share for Year
Press Release: Anika Therapeutics, Inc. – 19 hours ago
BEDFORD, Mass.--(BUSINESS WIRE)--
Anika Therapeutics, Inc. (ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the quarter and full year ended December 31, 2012. The company generated record quarterly and full year revenue in 2012.
Management Commentary
“In addition to achieving record quarterly and full year revenue, Anika delivered double-digit revenue and net income growth in the fourth quarter of 2012, concluding an excellent year from both financial and operational perspectives,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “These results were in line with the preliminary financial results we released on January 22, 2013.”
“Our top-line performance continues to be driven by strong demand for Orthovisc, our flagship orthobiologics product,” Sherwood said. “Orthovisc revenue in our U.S. market was up nearly 42% for the full year. Through the strength of our partner Depuy Mitek’s marketing activities over the past year, Orthovisc closed 2012 as the market leader in the U.S. multi-injection segment and the number two U.S. brand in viscosupplementation overall. On the bottom line, growing revenue, coupled with operating efficiencies, have enabled us to drive continued growth in income from operations and generate robust cash flow. Our financial performance remains strong despite a one time restructuring charge in the fourth quarter implemented to strengthen our business and refocus our development programs.”
“We have made progress in our efforts to secure U.S. regulatory approval for Monovisc®,” said Sherwood. “Subsequent to our Monovisc announcement on December 4, 2012, we completed an encouraging discussion with the FDA in January 2013 to determine our next steps. We followed up on that discussion by submitting a new PMA amendment incorporating existing data.”
“The year 2012 was successful for Anika, and we are well-positioned for further success in 2013,” Sherwood said. “Demand for Orthovisc is growing. We continue to streamline our operations and improve our manufacturing capabilities, and we are excited about our product pipeline. Anika is evolving from an HA biomaterials company into a products company focused on promising new medical solutions, and a company dedicated to capturing more of the value we have created by enhancing our capabilities in commercialization. We look forward to reporting our progress as the rest of 2013 unfolds.”
Revenue
Anika’s total revenue increased 23% to $22.6 million in the fourth quarter of 2012, from $18.4 million in the fourth quarter of 2011. For the full year 2012, total revenue grew 10% to $71.4 million, from $64.8 million a year earlier. The company’s revenue growth for both periods was primarily driven by increased sales of its flagship Orthobiologics product, Orthovisc®.
Product Gross Margin
Product gross margin for the fourth quarter of 2012 improved to 66.1%, from 59.8% in the fourth quarter last year. For the 12 months ended December 31, 2012, product gross margin increased to 57.4%, compared with 56.8% for full year 2011. The improvements for both the quarter and the year were driven by higher production volume, a more favorable product mix, and the realization of operational efficiencies from our new manufacturing facility after consolidation of sites.
Operating Income
Operating income for the fourth quarter of 2012 increased to $7.8 million, from $4.9 million in the same period in 2011. For the 12 months ended December 31, 2012, operating income increased to $19.7 million, from $14.0 million a year earlier. This growth was driven by a combination of increased revenue, higher product gross profit, lower R&D spending related to clinical studies, and reduced general and administrative expenses in 2012.
Net Income
Net income for the fourth quarter of 2012 rose to $4.5 million, or $0.31 per diluted share, from $2.9 million, or $0.21 per diluted share, in the fourth quarter last year. For full year 2012, net income grew to $11.8 million, or $0.82 per diluted share, from $8.5 million, or $0.62 per diluted share, in 2011. Net income for both 2012 periods includes, a one-time, pre-tax charge of $2.5 million related to the closure of the company’s tissue engineering facility in Italy. The company’s effective tax rate for 2012 increased to 39.8%, from 38.6% for 2011.
Operating Expenses
Research and development expenses for the fourth quarter of 2012 were $1.3 million, compared with $1.5 million in the fourth quarter last year. For the full year, R&D expenses decreased to $5.4 million, from $6.2 million in 2011. Anika expects a significant year-over-year increase in R&D expense for 2013 due to the anticipated initiation of a clinical study and new product pipeline initiatives.
Selling, general and administrative (“SG&A”) expenses in the fourth quarter of 2012 decreased to $3.7 million, from $4.9 million in the fourth quarter of 2011. For full year 2012, SG&A expenses decreased to $14.7 million, compared with $17.9 million in 2011. The declines for both periods were primarily due to U.S. manufacturing facilities consolidation, and the assumption of litigation costs by a third party.
Cash and Cash Equivalents
Anika’s cash and cash equivalents at December 31, 2012 increased to $44.1 million, from $35.8 million at December 31, 2011, driven by higher profits.
Conference Call Information
Anika will hold a conference call to discuss its financial results, business highlights and outlook tomorrow, Thursday, February 28, 2013 at 9:00 a.m. ET. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
To listen to the conference call, dial 800-291-5365 (international callers dial 617-614-3922) and use the passcode 89264114. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available through a live audio webcast in the “Investor Relations” section of the Anika Therapeutics website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The conference call will be archived and accessible on the same website shortly after the conclusion of the call.
surf1944
12 years ago
Anika Therapeutics Reports Record Second Quarter Revenue and Earnings
Total Revenue Grows 22%; Earnings Increase 53% to $0.26 per Share
Press Release: Anika Therapeutics, Inc. – 16 hours ago.. .
BEDFORD, Mass.--(BUSINESS WIRE)--
Anika Therapeutics, Inc. (ANIK), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the quarter ended June 30, 2012.
Revenue
For the second quarter of 2012, Anika’s total revenue increased 22% to $19.6 million, from $16.1 million in the second quarter last year. This growth was primarily driven by higher shipments of Anika’s ophthalmic products, as well as strong domestic and international sales of the company’s flagship product, Orthovisc®.
For the six-month period ended June 30, 2012, total revenue increased 22% to $34.0 million, from $27.9 million in the same period last year.
Product Gross Margin
Driven by higher production volume, product gross margin for the second quarter of 2012 increased to 57.2%, from 56.8% in the second quarter last year.
For the six-month period ended June 30, 2012, product gross margin increased to 55.4%, from 53.7% in the first six months of 2011.
Operating and Net Income
Operating income for the second quarter of 2012 increased to $6.1 million, from $3.7 million in the same period in 2011. Net income rose to $3.7 million, or $0.26 per diluted share, from $2.3 million, or $0.17 per diluted share, in the second quarter a year earlier. The company’s improved profitability was primarily driven by a combination of revenue growth, higher gross margin, and lower operating expenses. The company’s effective tax rate for the second quarter of 2012 was 38.6%, compared with 37.2% for the second quarter of 2011.
For the six-month period ended June 30, 2012, net income rose to $5.6 million, or $0.39 per diluted share, from $2.6 million, or $0.19 per diluted share, in the first six months of 2011.
Operating Expenses
Research and development expenses for the second quarter of 2012 decreased to $1.3 million, from $1.6 million in the second quarter last year. Anika continues to expect R&D expense to increase modestly in the second half of 2012 on a year-over-year basis due to the anticipated initiation of preclinical and clinical studies.
Selling, general and administrative expenses in the second quarter of 2012 decreased to $4.1 million, from $4.2 million in the second quarter of 2011. The decrease was primarily due to placing in service the remainder of the company’s Bedford manufacturing facility. Prior to the first quarter of 2012, the previously unoccupied space was expensed to SG&A.
Cash and Cash Equivalents
Anika’s cash and cash equivalents at June 30, 2012 were $37.9 million, compared with $34.0 million at March 31, 2012. The increase was primarily the result of higher profitability and collections on accounts receivable.
Management Commentary
“Anika concluded the first half of 2012 with all-time record quarterly revenue and record second-quarter earnings, while making solid progress toward key strategic goals,” said Charles H. Sherwood, Ph.D., president and chief executive officer. “Total revenue was up 22% from the second quarter last year, driven primarily by strong sales of our flagship product, Orthovisc®, both domestically and internationally and increased shipments in our Ophthalmic franchise. This growth was somewhat offset by year-over-year declines in sales of Monovisc®internationally, as well as slower sales of our products by Anika S.r.l.”
“We made solid operational progress in the second quarter,” said Sherwood. “We closed Anika’s facility in Woburn, Mass. and consolidated all of our manufacturing at our new facility in Bedford, Mass., by the end of the quarter as planned. We had a positive meeting with the FDA regarding our PMA application for Monovisc, and moved closer to starting patient enrollment in clinical trials for two key pipeline products.”
“Anika is starting the second half of 2012 with strong forward momentum,” Sherwood said. “Completing the manufacturing consolidation in Bedford allows us to strengthen our focus on our product pipeline and distribution network to drive top-line growth.”
surf1944
13 years ago
Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011
Earnings per share grow 144% to 22¢
Orthobiologics product revenue rises 35%, driven by growing Orthovisc® sales
Press Release Source: Anika Therapeutics, Inc. On Wednesday November 2, 2011, 4:01 pm EDT
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq:ANIK - News), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the third quarter ended September 30, 2011.
Revenue
For the third quarter of 2011, Anika’s revenue increased 33% to $18.5 million, from $13.9 million in the third quarter of 2010. This growth was driven by strong domestic and international sales of the company’s flagship product, Orthovisc®, as well as increased shipments of Anika’s ophthalmic and advanced wound care products.
For the nine-month period ended September 30, 2011, total revenue increased 13% to $46.3 million, from $40.8 million in the same period last year.
Operating and Net Income
Operating income for the third quarter of 2011 increased to $4.8 million, from $2.1 million in the same period in 2010. Net income rose to $3.0 million, or $0.22 per diluted share, from $1.2 million, or $0.09 per diluted share, in the third quarter of 2010. Anika’s effective tax rate for the third quarter of 2011 declined to 37.6% from 41.9% for the third quarter last year, primarily due to lower effective taxes on our Italian operations.
For the nine-month period ended September 30, 2011, net income rose 87% to $5.6 million, or $0.41 per diluted share, from $3.0 million, or $0.22 per diluted share, in the first nine months of 2010. This increase was a result of higher revenue, lower clinical study spending, and cost savings initiatives implemented in the past 21 months.
Product Gross Margin
Product gross margin for the third quarter of 2011 improved to 58%, from 54% in the third quarter last year. This improvement was driven by higher production volume.
For the nine-month period ended September 30, 2011, product gross margin was flat with the prior-year period at 56%.
Operating Expenses
Research and development expenses for the third quarter of 2011 declined to $1.5 million, from $1.8 million in the third quarter last year. The decrease in R&D expense was primarily due to lower clinical study spending compared to last year’s third quarter. R&D spending is expected to increase in future quarters. Selling, general and administrative expenses increased to $4.7 million, from $3.9 million in the third quarter a year ago. The increase in SG&A expenses was primarily due to foreign exchange losses on euro denominated assets caused by the strengthening of the U.S. dollar in September 2011.
Cash and Cash Equivalents
Anika’s cash and cash equivalents at September 30, 2011 rose to $29.0 million, from $28.2 million at December 31, 2010, mainly as a result of increased profits.
Management Commentary
“Fueled by 35% growth in product revenue and continued operational streamlining, this was an excellent quarter for Anika,” said Charles H. Sherwood, Ph.D., president and chief executive officer. “Our product revenue growth was driven by strong U.S. and international sales of Orthovisc, as well as increased shipments of our ophthalmic products and the advanced wound care products from Anika S.r.l. that we have added to our dermal franchise, highlighted by Hyalomatrix®. In addition to contributing to our top-line growth, Anika S.r.l. continued to reduce its net loss in the third quarter.”
“The FDA recently commenced its inspection of our manufacturing facility in Bedford, Mass.,” added Sherwood. “And we are scheduled to complete the migration of the majority of our manufacturing from Woburn, Mass., to Bedford in the first quarter of 2012. Overall, we are well on our way toward making 2011 a successful year for Anika.”
Conference Call Information
Anika will hold a conference call to discuss its financial results, business highlights and outlook tomorrow, Thursday, November 3, 2011 at 9:00 a.m. ET. In addition, the Company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed.
To listen to the conference call, dial 888-873-4896 (international callers dial 617-213-8850) and use the passcode 79317701. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available through a live audio webcast in the “Investor Relations” section of the Anika Therapeutics website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The conference call will be archived and accessible on the same website shortly after the conclusion of the call.
surf1944
13 years ago
Anika Therapeutics Announces U.S. Distribution Agreement for Advanced Wound Care Product
Misonix Named Exclusive Domestic Distributor of Anika’s Hyalomatrix® Skin Substitute
Press Release Source: Anika Therapeutics On Wednesday June 1, 2011, 4:15 pm EDT
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (Nasdaq:ANIK - News), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid (“HA”) technology, today announced Anika Therapeutics S.r.l., its wholly owned subsidiary, has entered into a new, five-year exclusive U.S. distribution agreement with Misonix, Inc. (Nasdaq:MSON - News), which will distribute and sell Anika’s Hyalomatrix®—an FDA-approved, HA-based skin substitute. One of the numerous products added to the Anika portfolio through its acquisition of Fidia Advanced Biopolymers (now Anika Therapeutics S.r.l.), Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds.
Anika will manufacture and supply finished product to Misonix, which will be responsible for all aspects of commercialization in the United States. A recognized leader in ultrasonic wound debridement, Misonix has dedicated U.S. sales and marketing organizations in both the clinical and surgical settings where acute and chronic wounds are treated.
“This is a promising new collaboration for Anika,” said Charles H. Sherwood, Ph.D., president and chief executive officer. “Misonix will be adding Hyalomatrix to its own proprietary technologies to create a comprehensive and leading-edge protocol for wound management. Given the knowledge of U.S. sales channels for wound care products that Misonix has acquired over the years, this agreement is an important milestone in Anika’s entry into the large and growing U.S. market for advanced wound treatment.”
surf1944
14 years ago
Anika Therapeutics Shares May Rebound
http://seekingalpha.com/article/268191-anika-therapeutics-shares-may-rebound?source=yahoo
Anika Therapeutics (NASDAQ:ANIK) develops and markets bio-polymer (based on naturally occurring polymer hyaluronic acid or HA) joint health and tissue repair products.
After the market close Wednesday, ANIK reported its 1Q11 results, which suffered from a one-time shipment delay (due to equipment problem at Woburn facility) of $1.4 million [M] that was shipped in April (i.e. likely to boost 2Q11 results) as manufacturing operations resumed.
- 1Q11 orthobiologic sales rose 16%, driven by continued strong US sales of ORTHOVISC and acquired Anika S.r.l. product sales increased 22% from year-ago period
- Product revenue declined 5% to $11.1M vs. $11.6M in the year-ago period and 1Q11 total revenue declined 5.8% to $11.7M vs. $12.5M in the year-ago period
- Adjusting for the $1.4M product shipment delay, 1Q11 product revenue would have been $12.5M (a 7.2% increase from the year-ago period)
- operating expenses declined during 1Q11, including R&D (research and development) expenses of $1.5M (vs. $1.9M in year-ago period) and SG&A (selling, general, and admin) expenses of $4M vs. $4.3M in year-ago period
- 1Q11 net income was $324,000 or $0.02 per diluted share vs. $714,000 or $0.05 per diluted share in year-ago period
- As of 3/31/11, had $29.1 million [M] cash / equivalents (up from $28.2M at year-end 2010 due to positive cash flow generated from operations) w/ $10.8M long-term debt and 13.5M shares of common stock outstanding
Below is a summary of four pending FDA medical device submissions for ANIK, which provided guidance on the 1Q11 conference call for a FDA reply within 60 days for MONOVISC following a recent meeting w/ the Agency that was conducted instead of the advisory panel meeting that ANIK previously requested to resolve questions surrounding the PMA. ANIK is also optimistic regarding approval of three pending 510(k) submissions for bio-polymer joint health products acquired w/ FAB that are currently marketed in Europe.
Product Candidate #1) MONOVISC (single-injection, bio-polymer arthritis product)
On 5/5/11, provided update following recent FDA meeting (conducted last week instead of advisory panel meeting that ANIK requested to resolve issues) and expects reply in 60 days (7/5/11 estimate) for PMA submitted in DEC 2009.
No safety issues were discussed and FDA is reviewing the efficacy results after a second submission by ANIK in late 2010 to address questions by the Agency over efficacy analyses performed in support of the PMA filing.
MONOVISC is designed as a follow-on product to ORTHOVISC as a single injection and six-month treatment duration for arthritis symptoms and has been marketed in Europe since 2Q08
Genzyme amended its lawsuit last week to add a third patent that expires after 2020, ANIK working to defend MONOVISC based on the revised claim by Genzyme
Product Candidates #1-4) FDA Decision 510(k) Medical Devices -- Hyalofast, Hyaloglide, and Hyalonect (Bio-Polymer Joint Health Products)
Estimated FDA decisions by mid-2011 (2-3Q11) for three joint health products marketed in Europe from FAB acquisition, including Hyalofast (adult, patient-derived bone marrow stem cell enriched tissue repair pad, Hyaloglide (healing aid gel w/ five-day duration for tendon / nerve surgeries) and Hyalonect (bone wrap mesh that is incorporated into the bone)
I added to my long position in ANIK on the sell-off due to weak quarterly results due to a one-time shipment delay that was sent in April (will be reflected in 2Q11 results), and I believe shares may rebound to the $10+ level now that the FDA has provided a 60-day window for an expected reply on the Company’s most important product candidate pending at FDA, MONOVISC, which is designed as a follow-on product to its top-selling joint health product ORTHOVISC.
In addition, 1Q11 results suffered from a one-time shipment delay to equipment problems that have since been resolved, so 2Q11 results are likely to benefit from the shortfall this quarter, and ANIK continues to enjoy a strong balance sheet with an increased cash position from year-end despite the weak quarterly results.
Disclosure: I am long ANIK.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Monksdream
3 months ago
whytestocks
6 years ago
Penny Roger$
13 years ago
Hot Features
Premium
